PolyPeptide also delivered a marked improvement in profitability in FY 2025, reaching between 11 - 12% EBITDA margin towards the upper end of guidance and up from 7.5% in 2024.

Fashion, beauty, and food companies are using nonsensical jargon to make a sale.

Investing.com -- PolyPeptide Group AG on Monday reported revenue of €389 million for the financial year 2025, representing a growth rate of 15.6% compared to the previous year.

Published, peer-reviewed research shows a patent-pending, virus-mimicking platform technology developed at Purdue University ...

When it comes to pharmacology, the big story these days is the development of the “glucagon-like peptide-1 (GLP-1) mimics,” ...

The president and his officials keep muddling their strategy.

PHILADELPHIA, Pennsylvania and COPENHAGEN, Denmark, Jan. 23, 2026 (GLOBE NEWSWIRE) -- Alveus Therapeutics, Inc. (“Alveus”), a clinical-stage ...

Diabetes care is undergoing a major transformation driven by GLP-1 receptor agonists, which have expanded beyond glycemic ...

The AACE has updated its guidance on obesity and adiposity-based chronic disease to reflect a focus on improving overall ...

Australians are buying an unapproved weight-loss drug from suppliers whose websites list the product as “for research use ...

Published, peer-reviewed research shows a patent-pending, virus-mimicking platform technology developed at Purdue University ...